(Q40036483)

16 September 2017

title

Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivates (English)

1 reference

16 September 2017

1 reference

Morisi R

1

1 reference

16 September 2017

Celano M

2

1 reference

16 September 2017

Tosi E

3

1 reference

16 September 2017

Schenone S

4

1 reference

16 September 2017

Navarra M

5

1 reference

16 September 2017

Ferretti E

6

1 reference

16 September 2017

Costante G

7

1 reference

16 September 2017

Durante C

8

1 reference

16 September 2017

Botta G

9

1 reference

16 September 2017

D'Agostino M

10

1 reference

16 September 2017

Brullo C

11

1 reference

16 September 2017

Filetti S

12

1 reference

16 September 2017

Botta M

13

1 reference

16 September 2017

Russo D

14

1 reference

16 September 2017

publication date

1 November 2007

1 reference

Journal of Endocrinological Investigation

16 September 2017

published in

1 reference

16 September 2017

volume

30

1 reference

16 September 2017

issue

10

1 reference

16 September 2017

page(s)

RC31-4

1 reference

Diagnosis and management of medullary thyroid carcinoma

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Antiproliferative effects of Src inhibition on medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

New pyrazolo[3,4-d]pyrimidines endowed with A431 antiproliferative activity and inhibitory properties of Src phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Cytogenetic characterization of three human and three rat medullary thyroid carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Cytotoxic effects of gemcitabine-loaded liposomes in human anaplastic thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Proteomic analysis of human thyroid cell lines reveals reduced nuclear localization of Mn-SOD in poorly differentiated thyroid cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

Selected glimpses into the activation and function of Src kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03349220

PP1 inhibitor induces degradation of RETMEN2A and RETMEN2B oncoproteins through proteosomal targeting

21 January 2018

1 reference

12 December 2020

The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes

1 reference

12 December 2020

Ret-mediated mitogenesis requires Src kinase activity.

1 reference

12 December 2020

Medullary thyroid carcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03349220

1 reference

Dimensions Publication ID

16 September 2017

1006354955

0 references

1 reference